Goldman Sachs Ups Edwards Lifesciences (EW) to Buy, On Product Cycle and Possible Take-Out; NUVA Downgraded

Goldman Sachs upgrades Edwards Lifesciences Corp. (NYSE: EW) from Neutral to Buy and raised their price target from $79 to $95, representing 25% upside. The firm said, "Edwards is the only company across our universe that has a new product cycle, which will drive future margin expansion." Goldman also said EW is the most likely take-out candidate in the group.

In the same report, Goldman downgraded NuVasive (Nasdaq: NUVA) from Buy to Neutral and lowered their price target form $49 to $45, saying they no longer see material upside to consensus estimates. Goldman said the core business will require more SG&A to drive top-line growth.

Real-Time Market Moving News - Two Weeks Free http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
• Canaccord Genuity Maintains a 'Hold' on Tiffany & Co. (TIF); Cutting PT and Estimates
• UBS Maintains a 'Neutral' on VeriFone (PAY); Europe Demand Healthy, but FX Emerges as Headwind

Create E-mail Alert Related Categories

Downgrades, Rumors, Trader Talk, Upgrades

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter